Neratinib after trastuzumab in patients with HER2-positive breast cancer - Author's reply

by Chan, Arlene, Buyse, M., Yao, B.
Published 2016

Assessing the benefit–risk of new treatments using generalised pairwise comparisons: the case of erlotinib in pancreatic cancer

by Péron, J, Roy, P, Ding, K, Parulekar, W R, Roche, L, Buyse, M
Published 2015

Designing phase II trials in cancer: a systematic review and guidance

by Brown, S R, Gregory, W M, Twelves, C J, Buyse, M, Collinson, F, Parmar, M, Seymour, M T, Brown, J M
Published 2011

Gene expression profiling in breast cancer challenges the existence of intermediate histological grade

by Sotiriou, C, Wirapati, P, Loi, S, Harris, A, Bergh, J, Smeds, J, Praz, V, Farmer, P, Haibe-Kains, B, Lallemand, F, Buyse, M, Piccart, M, Delorenzi, M
Published 2005

Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epiderman growth factor receptor 2-normal,...

by Eiermann, W., Pienkowski, T., Crown, J., Sadeghi, S., Chan, Arlene, Saleh, M., Sehdev, S., Provencher, L., Semiglazov, V., Press, M., Sauter, G., Lindsay, M., Riva, A., Buyse, M., Drevot, P., Taupin, H., Mackey, J.
Published 2011

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): A multicentre, randomised, double-blind, placebo-controlled, phase 3 tria...

by Chan, Arlene, Delaloge, S., Holmes, F., Moy, B., Iwata, H., Harvey, V., Robert, N., Silovski, T., Gokmen, E., von Minckwitz, G., Ejlertsen, B., Chia, S., Mansi, J., Barrios, C., Gnant, M., Buyse, M., Gore, I., Smith, J., Harker, G., Masuda, N., Petrakova, K., Zotano, A., Iannotti, N., Rodriguez, G., Tassone, P., Wong, A., Bryce, R., Ye, Y., Yao, B., Martin, M.
Published 2016

Adjuvant trastuzumab in HER2-positive breast cancer.

by Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., Mackey, J., Glaspy, J., Chan, Arlene, Pawlicki, M., Pinter, T., Valero, V., Liu, M., Sauter, G., von Minckwitz, G., Visco, F., Bee, V., Buyse, M., Bendahmane, B., Tabah-Fisch, I., Lindsay, M., Riva, A., Crown, J., Breast, C.
Published 2011

Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group.

by Aabo, K., Adams, M., Adnitt, P., Alberts, D. S., Athanazziou, A., Barley, V., Bell, D. R., Bianchi, U., Bolis, G., Brady, M. F., Brodovsky, H. S., Bruckner, H., Buyse, M., Canetta, R., Chylak, V., Cohen, C. J., Colombo, N., Conte, P. F., Crowther, D., Edmonson, J. H., Gennatas, C., Gilbey, E., Gore, M., Guthrie, D., Yeap, B. Y.
Published 1998

Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patients

by Haibe-Kains, B., Desmedt, C., Di Leo, A., Azambuja, E., Larsimont, D., Selleslags, J., Delaloge, S., Duhem, C., Kains, J.P., Carly, B., Maerevoet, M., Vindevoghel, A., Rouas, G., Lallemand, F., Durbecq, V., Cardoso, F., Salgado, R., Rovere, R., Bontempi, G., Michiels, S., Buyse, M., Nogaret, J.M., Qi, Y., Symmans, F., Pusztai, L., D'Hondt, V., Piccart-Gebhart, M., Sotiriou, C.
Published 2013